ZyVersa Therapeutics Inc. (ZVSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ZyVersa Therapeutics Inc. (ZVSA) has a cash flow conversion efficiency ratio of 119.987x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.41 Billion) by net assets ($-11.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is ZyVersa Therapeutics Inc. worth for the company's overall valuation and market capitalisation.
ZyVersa Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how ZyVersa Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
ZyVersa Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ZyVersa Therapeutics Inc. ranked by their cash flow conversion efficiency. See ZyVersa Therapeutics Inc. cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Regent Pacific Properties Inc
V:RPP
|
0.061x |
|
GIGLIO GROUP S.P.A. O.N.
F:5JR
|
N/A |
|
Future Enterprises Limited
NSE:FELDVR
|
-0.222x |
|
Condmag Brasov
RO:COMI
|
0.067x |
|
Olenox Industries Inc.
NASDAQ:OLOX
|
-0.026x |
|
Noratis AG
XETRA:NUVA
|
0.070x |
|
Yimutian Inc. American Depositary Shares
NASDAQ:YMT
|
0.001x |
|
Tessin Nordic Holding AB
ST:TESSIN
|
0.101x |
Annual Cash Flow Conversion Efficiency for ZyVersa Therapeutics Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of ZyVersa Therapeutics Inc. from 2020 to 2024. View ZyVersa Therapeutics Inc. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.52 Million | $-7.56 Million | -0.888x | -12.72% |
| 2023-12-31 | $11.07 Million | $-8.72 Million | -0.787x | -1510.74% |
| 2022-12-31 | $99.99 Million | $-4.89 Million | -0.049x | -112.04% |
| 2021-12-31 | $-12.50 Million | $-5.08 Million | 0.406x | -31.99% |
| 2020-12-31 | $-8.56 Million | $-5.11 Million | 0.597x | -- |
About ZyVersa Therapeutics Inc.
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glome… Read more